# Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition

> **NCT04542291** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 15 (actual)

## Conditions studied

- Pancreas Cancer
- Pancreatic Cancer
- Cancer of the Pancreas

## Interventions

- **DRUG:** Dapagliflozin
- **DEVICE:** BIOSENSE meters

## Key facts

- **NCT ID:** NCT04542291
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-25
- **Primary completion:** 2021-12-24
- **Final completion:** 2022-01-19
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-02-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04542291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04542291, "Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04542291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*